Oncology Institute (NASDAQ:STLN) Director Brad Hively Sells 298,853 Shares of Stock

by · The Cerbat Gem

Oncology Institute, Inc. (NASDAQ:STLN – Get Free Report) Director Brad Hively sold 298,853 shares of the stock in a transaction on Friday, August 21st. The shares were sold at an average price of $6.51, for a total value of $1,945,533.03. Following the completion of the transaction, the director directly owned 411,976 shares in the company, valued at approximately $2,681,963.76. This represents a 42.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oncology Institute Stock Down 5.3%

STLN stock traded down $0.34 during mid-day trading on Monday, hitting $6.13. 1,228,983 shares of the stock were exchanged, compared to its average volume of 1,888,221. Oncology Institute, Inc. has a 12 month low of $2.32 and a 12 month high of $7.05. The firm has a market cap of $605.89 million, a P/E ratio of -20.43 and a beta of 0.39.

Oncology Institute (NASDAQ:STLN – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The company reported ($0.08) EPS for the quarter. The firm had revenue of $161.28 million during the quarter, compared to analysts’ expectations of $152.80 million. As a group, research analysts expect that Oncology Institute, Inc. will post -0.21 EPS for the current fiscal year.

Institutional Investors Weigh In On Oncology Institute

A hedge fund recently bought a new stake in Oncology Institute stock. AXQ Capital LP purchased a new position in shares of Oncology Institute, Inc. (NASDAQ:STLN – Free Report) during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm purchased 22,460 shares of the company’s stock, valued at approximately $122,000. 36.86% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings assumed coverage on shares of Oncology Institute in a report on Thursday, August 6th. They issued a “sell (d-)” rating for the company. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock has a consensus rating of “Sell”.

Get Our Latest Analysis on STLN

Oncology Institute Company Profile

(Get Free Report)

Oncology Institute is a physician-led healthcare company focused on delivering specialized cancer care through an integrated oncology platform. Its services are designed to support patients throughout the cancer-care journey, including diagnosis, treatment planning, chemotherapy and other medical oncology services, supportive care, and ongoing disease management.

The company’s business model emphasizes value-based oncology care, with care coordination and clinical programs intended to improve outcomes while managing the overall cost of treatment.

See Also